Recent Posts
Anaveon appoints Dr Eduard Gasal as Chief Medical OfficerNovember 30, 2022
Anaveon presents updated data from the Phase I/II study of ANV419 during the SITC Annual MeetingNovember 10, 2022
Anaveon announces upcoming poster presentations at the 37th Society for Immunotherapy of Cancer Annual MeetingOctober 31, 2022